What is Treos Bio?
Treos Bio operates at the intersection of biotechnology and oncology, specializing in the development of next-generation peptide active cancer immunotherapies. The company addresses the critical challenge of tumor and patient heterogeneity by creating proprietary therapeutic peptides that elicit robust immune responses across diverse genetic profiles. Unlike traditional personalized medicine approaches that often require invasive tumor biopsies, Treos Bio's platform offers a scalable, off-the-shelf solution. Their lead candidate, PolyPEPI1018, is currently undergoing rigorous evaluation for its efficacy in treating colorectal cancer, demonstrating the potential to provide accessible, high-impact treatment options on a global scale.
How much funding has Treos Bio raised?
Treos Bio has raised a total of $22M across 2 funding rounds:
Private Equity
$8M
Debt
$14M
Private Equity (2017): $8M, investors not publicly disclosed
Debt (2021): $14M led by Future Fund and Luminous Ventures
Key Investors in Treos Bio
Future Fund
A sovereign wealth fund established to invest for the benefit of future generations, focusing on long-term financial sustainability and public sector superannuation liabilities.
Luminous Ventures
A venture capital firm specializing in early-stage and growth-stage investments within the deep tech and life sciences sectors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Treos Bio?
With the recent capital deployment, Treos Bio is poised to transition into a more mature phase of clinical development. The strategic focus will likely center on advancing the PolyPEPI1018 program through late-stage trials and expanding the underlying platform's utility across additional oncology indications. As the company scales its operations, the emphasis will remain on validating the clinical utility of its peptide-based approach, potentially setting a new standard for immunotherapy accessibility. Investors are closely monitoring the firm's ability to navigate the complex regulatory landscape while maintaining its competitive edge in the rapidly evolving immuno-oncology market.
See full Treos Bio company page
